Charles Schwab’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $57.9M | Buy |
406,133
+21,747
| +6% | +$3.3M | 0.01% | 1128 |
|
|
2026
Q2 | $60.2M | Buy |
384,386
+38,976
| +11% | +$5.84M | 0.01% | 1121 |
|
|
2026
Q1 | $52.8M | Buy |
345,410
+54,930
| +19% | +$8.42M | 0.01% | 1120 |
|
|
2025
Q4 | $40M | Buy |
290,480
+29,653
| +11% | +$3.88M | 0.01% | 1296 |
|
|
2025
Q3 | $33.4M | Buy |
260,827
+38,197
| +17% | +$4.66M | 0.01% | 1410 |
|
|
2025
Q2 | $26.9M | Buy |
222,630
+37,027
| +20% | +$4.17M | ﹤0.01% | 1506 |
|
|
2025
Q1 | $20.7M | Buy |
185,603
+20,161
| +12% | +$2.15M | ﹤0.01% | 1626 |
|
|
2024
Q4 | $16.1M | Buy |
165,442
+8,186
| +5% | +$873K | ﹤0.01% | 1805 |
|
|
2024
Q3 | $18.1M | Buy |
157,256
+18,990
| +14% | +$2.15M | ﹤0.01% | 1745 |
|
|
2024
Q2 | $14.7M | Buy |
138,266
+17,662
| +15% | +$1.77M | ﹤0.01% | 1846 |
|
|
2024
Q1 | $11.6M | Sell |
120,604
-25,805
| -18% | -$2.65M | ﹤0.01% | 1914 |
|
|
2023
Q4 | $14.6M | Sell |
146,409
-4,237,440
| -97% | -$409M | ﹤0.01% | 1787 |
|
|
2023
Q3 | $416M | Sell |
4,383,849
-28,592
| -0.6% | -$2.9M | 0.12% | 145 |
|
|
2023
Q2 | $417M | Sell |
4,412,441
-49,942
| -1% | -$5M | 0.12% | 142 |
|
|
2023
Q1 | $384M | Sell |
4,462,383
-106,331
| -2% | -$9.29M | 0.12% | 147 |
|
|
2022
Q4 | $389M | Buy |
4,568,714
+41,253
| +0.9% | +$3.47M | 0.13% | 155 |
|
|
2022
Q3 | $344M | Buy |
4,527,461
+83,210
| +2% | +$6.9M | 0.12% | 152 |
|
|
2022
Q2 | $376M | Buy |
4,444,251
+45,038
| +1% | +$3.95M | 0.13% | 144 |
|
|
2022
Q1 | $386M | Buy |
4,399,213
+193,519
| +5% | +$16.8M | 0.12% | 157 |
|
|
2021
Q4 | $368M | Buy |
4,205,694
+89,226
| +2% | +$7.41M | 0.11% | 163 |
|
|
2021
Q3 | $337M | Buy |
4,116,468
+38,337
| +0.9% | +$3.45M | 0.11% | 162 |
|
|
2021
Q2 | $372M | Buy |
4,078,131
+58,840
| +1% | +$5.24M | 0.12% | 147 |
|
|
2021
Q1 | $344M | Sell |
4,019,291
-544,058
| -12% | -$48.8M | 0.13% | 143 |
|
|
2020
Q4 | $431M | Sell |
4,563,349
-232,491
| -5% | -$20.3M | 0.17% | 114 |
|
|
2020
Q3 | $417M | Sell |
4,795,840
-260,053
| -5% | -$22.5M | 0.19% | 104 |
|
|
2020
Q2 | $442M | Sell |
5,055,893
-172,708
| -3% | -$14.9M | 0.22% | 96 |
|
|
2020
Q1 | $431M | Buy |
5,228,601
+4,323,827
| +478% | +$386M | 0.25% | 84 |
|
|
2019
Q4 | $85.7M | Buy |
904,774
+142,947
| +19% | +$12.8M | 0.05% | 384 |
|
|
2019
Q3 | $66.2M | Buy |
761,827
+88,776
| +13% | +$7.97M | 0.04% | 444 |
|
|
2019
Q2 | $61.5M | Buy |
673,051
+128,555
| +24% | +$10.9M | 0.04% | 475 |
|
|
2019
Q1 | $46.9M | Buy |
+544,496
| New | +$43.7M | 0.03% | 574 |
|
Other funds holding NVS
Charles Schwab's NVS Position: Q3 2026 in Review
Charles Schwab increased its Novartis (NVS) stake by 5.7% in Q3 2026, buying an estimated $3.3M and bringing the position to 406,133 shares worth $57.9M. The position accounts for 0.01% of the portfolio, ranked #1128.
Charles Schwab first reported a position in NVS in Q1 2019 and has held it in 31 quarters since. The position peaked at $442M in Q2 2020. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.
- Charles Schwab held 406,133 shares of Novartis worth $57.9M as of Q3 2026.
- Charles Schwab bought 21,747 Novartis shares in Q3 2026, an estimated $3.3M.
- Novartis made up 0.01% of Charles Schwab's portfolio in Q3 2026, its #1128 holding.
- Charles Schwab first reported a position in Novartis in Q1 2019 and has held it in 31 quarters since.
- Charles Schwab's Novartis position peaked at $442M in Q2 2020.
- 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.
Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.